Monday, November 21, 2016 7:22:31 AM
Is Valeant Pharmaceuticals the Turnaround Opportunity of a Lifetime?
To some, the drugmaker deserves a spot alongside infamous failures like Enron. To others, though, this beaten-down stock offers the potential of an enormous rebound.
Keith Speights
(TMFFishBiz)
Nov 18, 2016
They say that one man's trash is another man's treasure, and Valeant Pharmaceuticals (NYSE:VRX) stock probably fits in the trash category for many right now. Shares of the embattled drugmaker have nose-dived more than 80% in 2016. However, CEO Joe Papa sees his company as a potential treasure. At this week's Stifel Healthcare Conference, Papa said that "Valeant is the turnaround opportunity of a lifetime."
Here's how he thinks Valeant can make this statement become a reality.
Valeant's biggest problem is its $30 billion of debt. One way that the company's executives plan to reduce that is by selling off assets. But which parts of its business is it willing to sell?
Papa reiterated in his comments at the conference this week that Valeant's preference is to sell non-core assets. He defined core assets in two ways: by business segment and geography. By business segments, he said, Bausch + Lomb eye care, dermatology, and consumer products qualify, and geographically, the U.S. and Canada are its core markets. That theoretically leaves everything else as non-core -- and potentially up for sale.
The company previously committed to reducing its debt by around $5 billion by early 2018. Papa said that selling non-core assets could generate proceeds of roughly $8 billion -- which is more than Valeant's current market cap of $6.3 billion.
Moreover, Papa didn't rule out selling core assets. "If somebody puts in an offer that is significant, will have to evaluate those offers," he said. According to The Wall Street Journal, that's exactly what has happened. The newspaper reported earlier in November that Japanese pharmaceutical company Takeda is interested in buying Valeant's Salix business for around $10 billion. There could be another bidder for Salix as well.
Restoring growth
While selling off assets could help Valeant lower its debt load, that's not enough to turn things around entirely. Papa acknowledged that the company must also return to growth, a goal he thinks is achievable.
In his view, Valeant has already made the correct first step by "resetting the team." He mentioned key executive changes made over the last several months, including hiring a new CFO, controller, head of quality, and general counsel.
Another important element to restoring growth will be repairing Valeant's relationship with Walgreens (NASDAQ:WBA). Papa has mentioned in the past that there were some initial problems with the pharmacy chain, particularly with pricing for some products. However, he said that there has been "great progress" in the past three to four months, with dermatology average selling prices now up around 40%.
There is "still work to do," according to Papa, but he remains confident that the long-term agreement between the two companies will pay off and is excited about its prospects.
The most important ingredients in the growth recipe, though, will be new products, and Papa put anti-inflammatory drug brodalumab at the top of the list. He also has high expectations for glaucoma drug latanoprostene bunod. Although the Food and Drug Administration rejected the drug in July over issues at a manufacturing facility, Papa thinks Valeant should have those issues addressed by the end of the year and could launch the product by mid-2017.
One growth driver mentioned by Papa might not be around if a sale of the Salix business goes through. Xifaxan, which treats irritable bowel syndrome with diarrhea (IBS-D), has been one of the few bright spots for Valeant this year.
Great opportunity or another Enron?
Well-known value investor Bill Miller recently said that he thinks Valeant stock is worth twice its current price. On the other hand, Jim Chanos, founder and managing partner of Kynikos Associates, stated this week that "Valeant epitomizes everything that went wrong with the marketplace." Chanos went on to say that hedge funds have lost more money on the pharmaceutical company than they did on failed energy company Enron.
Although Chanos' assertion about funds losing a lot of money on Valeant is correct, I suspect that Papa and Miller could be right over the long run. A sale of the Salix business would be a good start. Selling off other non-core assets would also help. So would improving the Walgreens relationship and launching new products like brodalumab.
The company has a long way to go and a lot of risks remaining, though. Valeant can't afford to stumble by executing poorly. Still, I think this trashed stock could possibly turn into treasure given enough time. it just might be "the turnaround opportunity of a lifetime."
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent BHC News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:24:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:19:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:16:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 03:36:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 10:04:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:04:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:30:26 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/08/2024 02:00:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 10:18:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:19:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:18:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:15:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 09:35:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/05/2023 04:12:39 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/13/2023 09:50:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/06/2023 10:06:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/06/2023 04:09:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:58:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 11:05:39 AM
- Bausch Health Gets FDA Approval for Acne Treatment Cabtreo • Dow Jones News • 10/20/2023 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 08:29:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 08:28:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 08:27:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 08:25:30 PM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM